Thibault R, Welch S, Mauras N, Sager B, Altomare A, Haymond M, Darmaun D. Corticosteroids increase glutamine utilization in human splanchnic bed. Am J Physiol Gastrointest Liver Physiol 294: G548-G553, 2008. First published December 27, 2007 doi:10.1152/ajpgi.00461.2007.-Glutamine is the most abundant amino acid in the body and is extensively taken up in gut and liver in healthy humans. To determine whether glucocorticosteroids alter splanchnic glutamine metabolism, the effect of prednisone was assessed in healthy volunteers using isotope tracer methods. Two groups of healthy adults received 5-h intravenous infusions of L-[1-14 C]leucine and L-[ 2 H5]glutamine, along with q. 20 min oral sips of tracer doses of L-[1-
can be used to assess the extraction of glutamine by the splanchnic bed. By using this technique, ϳ50 to 75% of enterally administered glutamine undergoes first-pass extraction within the splanchnic bed, presumably by the gut and liver, in healthy humans (4, 17, 18, 34) . Additionally, the major fate of splanchnic glutamine after enteral administration was oxidation, since 83% of the total tracer extracted was oxidized and only 10% was used for gluconeogenesis (17) .
A dramatic rise in the rate of glutamine uptake in splanchnic tissues has been documented in animal models of stress or after administration of glucocorticoids, which are believed to mediate some of the protein catabolic response to stress (2, 27, 38, 40, 42) . It is well known that glucocorticoids mimic some of the alterations in amino acid metabolism observed in stressinduced protein wasting (5, 24, 35) . In humans, little is known about the effect of stress or glucocorticoids on glutamine uptake in splanchnic tissues. A single study showed that postoperative stress following coronary bypass surgery was associated with an increased splanchnic extraction of glutamine (41) . To our knowledge, the effects of glucocorticoids on splanchnic glutamine metabolism have not been studied in humans. The aim of this study was to determine, in healthy adult volunteers, whether a 6-day treatment with prednisone alters first-pass glutamine extraction in the splanchnic bed and glutamine oxidation, as assessed with isotopic methods.
MATERIALS AND METHODS

Materials. L-[1-
14 C]leucine (Ͼ55 mCi/mmol; New England Nuclear, Boston, MA) and L- [1- 13 C]glutamine (99% 13 C) and L-[
2 H5]glutamine (98% 2 H5) (both stable isotopes from Cambridge Isotope Laboratories, Woburn, MA) were mixed with 0.9% saline and tested for chemical, isotopic, and optical purity by high-performance liquid chromatography (HPLC) and gas chromatography-mass spectrometry (GCMS) for radioactive and stable isotope tracers, respectively, and verified to be sterile (plate culture) and pyrogen free (Limulus lysate assay). Solutions were passed through a 0.22-m Millipore filter and stored in sterile containers at 4°C for Ͻ24 h prior to use.
Experimental design. This protocol was reviewed and approved by the Nemours Children's Clinic Research Committee and the Institutional Review Committee at Baptist Medical Center, Jacksonville, FL. Subjects were judged to be free of any chronic or acute illness based on detailed medical history, physical exam, and routine blood chemistry. Women had to have a negative pregnancy test within 48 h of study and could not be breastfeeding. Both groups of healthy volun-teers received detailed information on the purpose and potential risks of the study and were enrolled after signing a written consent form. A dietary history was obtained, and subjects were instructed to maintain their usual intake and their regular level of activity for 6 days prior to isotope infusion. Subjects were enrolled into either a control group (group 1; n ϭ 6) or a prednisone group (group 2; n ϭ 8). Subjects enrolled into group 2 received a 6-day course of treatment with prednisone (0.8 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 , with a maximum dose set at 60 mg/day) split in three daily doses; in contrast, subjects enrolled in group 1 (controls) did not receive any medication prior to the isotope infusion. Data concerning glutamine splanchnic uptake were obtained in five of six control subjects, and data concerning glutamine oxidation were available in seven of eight prednisone-treated subjects.
Isotope infusion protocol. For each protocol, the night before each infusion study day, each subject ate dinner at 1800 and then remained fasting (with the exception of water and calorie-free, caffeine-free drinks) until completion of the infusion study at 1300 the following day. On the next morning at 0700, each subject was studied as an outpatient in the Baptist Medical Center/Wolfson Children's Hospital Clinical Investigation Unit. Two short catheters were inserted, one in a forearm vein for isotope infusion and the other one in a superficial vein of the contralateral hand; the hand was placed in a warming pad at ϳ60°C to obtain arterialized venous blood samples (1) . Five-hour continuous infusions of tracers were administered in the postabsorptive state between 0800 and 1300, as follows:
) was administered intravenously; and 2) L-[1- Arterialized venous blood samples were obtained 30 and 15 min before the start and at 30-min intervals between the second and the fifth hour of isotope infusion. Plasma was analyzed for the isotopic enrichment of glutamine and specific activity of plasma ␣-ketoisocaproate (KIC), respectively. Aliquots of expired air were collected before the start and during the last 2 h of isotope infusion to determine breath 13 CO2 enrichments. The rate of respiratory 14 CO2 excretion (dpm/min) was determined by obtaining timed 2-min collections of expired air into Douglas bags via a mouthpiece equipped with a one-way valve; the CO2 in the collected air was then quantitatively trapped by slowly bubbling the expired air into a solution of ethanolamine (36) . Breath air 14 CO2 specific activity (dpm/mmol) was determined by bubbling aliquots of expired air through 2 ml of a 0.5 mmol/l hyamine solution as described (36) .
Analytical methods. Plasma amino acid concentrations were determined by ion-exchange chromatography with a Beckman 6300 amino acid analyzer (Beckman Instruments, Palo Alto, CA). Breath 13 CO2 enrichments were measured by gas chromatography-isotope ratio mass spectrometry (Isochrom III, VG, Ipswich, UK). Plasma [
13 C] and [
2 H5]glutamine enrichments were determined by selected ion monitoring GCMS (Hewlett-Packard MSD 5971) as described previously (10). Plasma [
14 C]KIC specific activity was determined by HPLC (on a Spectraphysics SP8800 instrument equipped with a Pharmacia LKB Frac 200 fraction collector) as described previously (23) . The 14 C-specific activity of KIC fractions and breath CO2 was measured on a Beckman LS6500 scintillation counter.
Calculations. Appearance rate (Ra) of leucine into plasma (RaLEU; mol ⅐ kg Ϫ1 ⅐ h Ϫ1 ) was calculated by using standard isotope dilution equations for steady-state conditions as described in earlier studies: RaLEU ϭ iLEU/SAKIC, where iLEU is the rate of [
14 C]leucine infusion (dpm ⅐ kg Ϫ1 ⅐ h Ϫ1 ) and SAKIC is the 14 C-specific activity of plasma KIC (dpm/mol) at isotopic steady state. Because leucine is an essential amino acid, the only source of leucine Ra in postabsorptive subjects is leucine release from the breakdown of body protein (34) .
Leucine oxidation (OxLEU; mol ⅐ kg Ϫ1 ⅐ h Ϫ1 ) was calculated on the basis of the excretion of labeled CO2 in expired air: OxLEU ϭ ) and 0.7 is the assumed fractional recovery of labeled carbon in expired air in the postabsorptive state (22) .
Nonoxidative leucine disposal (NOLD; mol ⅐ kg Ϫ1 ⅐ h Ϫ1 ) was calculated as NOLD ϭ Ra LEU Ϫ OxLEU. Because leucine is assumed to be either oxidized or incorporated into protein, NOLD is an index of whole body protein synthesis (34) .
Glutamine appearance into the plasma compartment (Ra GLN; ]glutamine enrichments (mole percent excess) in the infused tracer solution and plasma at steady state, respectively. Ra GLN is an index of interorgan glutamine exchange between tissues (12) .
Glutamine release from protein breakdown. Because glutamine is a nonessential amino acid, both glutamine release from protein breakdown (BGLN) and glutamine de novo synthesis (DGLN) contribute to glutamine Ra. Although body protein is known to contain 13.9 g of glutamine ϩ glutamate per 100 g protein, the exact contribution of glutamine per se to that total amount is not precisely known. Recently, by using a novel analytical tool, human skeletal muscle protein was, however, shown to contain only 4.32 g glutamine per 100 g of bound amino acid residues. B GLN was therefore estimated as 0.423 ϫ Ra LEU (28) . This approach assumes that 1) the release of an amino acid from proteolysis is proportional to its abundance in body protein; 2) 100 g of body protein contain 9,180 mg leucine, i.e., 70.1 mmol leucine (as 1 mmol leucine ϭ 131 mg, and 9,180/131 ϭ 70.1); and ϳ4,320 mg glutamine (ϭ29.6 mmol glutamine since 1 mmol glutamine ϭ 146 mg, and 4,320/146 ϭ 29.6), or 0.423 mol glutamine per mol leucine (29.6/70.1 ϭ 0.423).
Glutamine de novo synthesis. The fraction of glutamine Ra that cannot be accounted for by release of glutamine from protein breakdown was attributed to D GLN. DGLN was therefore estimated by DGLN ϭ Ra GLN Ϫ BGLN (28) .
Splanchnic glutamine uptake. The model used to quantify splanchnic glutamine uptake in the present studies is similar to that used in healthy subjects by us (4, 18) and others (17) Glutamine oxidation. The respiratory excretion of 13 C-labeled carbon dioxide was calculated as (E CO 2 ϫ V CO2)/0.7, where V CO2 is the rate of CO2 excretion (mol ⅐ kg Ϫ1 ⅐ h Ϫ1 ), E CO 2 is steady-state 13 CO2 enrichment (mole percent excess) in expired air, and 0.7 is the assumed fractional recovery of labeled carbon in expired air in the postabsorptive state (22) . The percentage of enterally infused glutamine that underwent oxidation (FoxGLN) was estimated by FoxGLN ϭ 100 ϫ
Statistical analysis. During the tracer infusions, steady state for plasma amino acid levels and enrichments was defined by the absence of a significant correlation of the measured parameter vs. time over the considered period. Statistical analyses were performed with Statview 4.5 and SAS 9.1 statistical software (SAS Institute, Cary, NC).
Normality of the distribution was tested with the Kolmogorov-Smirnov test. If normally distributed, continuous variables were reported as means Ϯ SE and compared between prednisone-treated and control groups by Student's t-test. If nonnormally distributed, continuous variables were reported as medians Ϯ interquartiles and compared between prednisone-treated and control groups by Mann-Whitney U-test. Categorical variables (sex) were reported as number of patients and compared by Fisher exact test. P values Ͻ0.05 were considered to be statistically significant.
RESULTS
Subjects characteristics.
The clinical characteristics of the subjects studied are summarized in Table 1 . No differences were observed between the two groups (e.g., sex, age, height, weight, and body mass index).
Leucine metabolism. Results of leucine kinetics are reported in Table 2 . Plasma leucine and glutamine concentrations were near steady state during the 5 h of each isotope infusion study. Leucine concentration was significantly higher (P ϭ 0.03) in prednisone-treated patients than in controls. No differences were observed in leucine Ra, leucine oxidation, and nonoxidative leucine disposal between the two groups (Fig. 1) .
Glutamine metabolism. As expected, glutamine concentrations were higher (P ϭ 0.02) in the prednisone group. Prednisone treatment increased glutamine Ra by ϳ37%, compared with the control group (medians Ϯ interquartiles, 477.2 Ϯ 60.2 vs. 346.8 Ϯ 198.5 mol⅐ kg Ϫ1 ⅐h Ϫ1 , P ϭ 0.003) ( Table 3 and Fig. 2 ). The increase in glutamine Ra was mostly due to an ϳ47% rise in glutamine de novo synthesis in the prednisone group (medians Ϯ interquartiles, 412.0 Ϯ 61.3 vs. 279.9 Ϯ 190.4 mol⅐kg Ϫ1 ⅐ h
Ϫ1
, P ϭ 0.003), since glutamine release from protein breakdown did not differ between groups (mean Ϯ SE, 65.2 Ϯ 2.0 vs. 59.6 Ϯ 4.3 mol⅐kg Ϫ1 ⅐h
, NS) (Fig. 2) .
Glutamine uptake and oxidation. Results of glutamine splanchnic uptake and glutamine oxidation are reported in Tables 4 and 5 , respectively. Dietary [
13 C]glutamine Ra and splanchnic extraction rate of [ 13 C]glutamine were ϳ68 and ϳ525% higher, respectively, in the prednisone group, compared with controls. Thus prednisone resulted in a 50% increase in the splanchnic extraction of glutamine (Table 4 and Fig. 3 ). In contrast, although breath 13 CO 2 excretion and breath 13 C enrichment were higher (increased by 216 and 236%, respectively, P Ͻ 0.01) in the prednisone group, the fraction of glutamine oxidized (as calculated from steady-state 13 CO 2 in expired air) was not statistically different between the prednisone and control groups (Table 5 and Fig. 3 ). The increased rate of glutamine splanchnic uptake observed in prednisonetreated healthy volunteers therefore was not associated with an increased rate of glutamine oxidized.
DISCUSSION
Using stable isotope methodology in volunteers receiving prednisone treatment, a model of mild, stress-induced protein wasting, the present study provides evidence for an increased rate of splanchnic extraction of glutamine. Since prednisone treatment did not increase glutamine oxidation, the present findings demonstrate that high-dose glucocorticosteroids enhance the rate of glutamine utilization via nonoxidative pathways.
Prednisone increased plasma leucine concentration but had no effect on leucine Ra, which is in contrast to our previous studies. We believe that this was the result of intersubject variability that precluded statistical significance. Treatment Values are means Ϯ SE. Leu, leucine; Ra, rate of appearance; Ox, oxidation; NOLD, nonoxidative leucine disposal. with glucocorticosteroids nevertheless increased glutamine Ra and de novo synthesis, as observed in earlier reports (6, 11) . Glucocorticosteroids indeed enhance glutamine de novo synthesis in rats (14) , dogs (24) , and humans (11) . As already reported in hypercatabolic or corticosteroid-treated patients (5, 16, 26) , the de novo synthesis of glutamine most likely occurs in peripheral tissues.
Nevertheless, a large body of evidence from earlier studies suggest that, in a clinical setting of stress-induced hypercatabolism, i.e., in patients admitted to intensive care unit (ICU) or patients with severe burn, depletion in plasma glutamine concentration occurs (16, 26) . Therefore, glutamine is considered by many as a conditionally essential amino acid in the ICU (29) . The specific mechanisms responsible for glutamine depletion in stress continue to be debated. From a theoretical standpoint, glutamine depletion can arise either from an insufficient production rate, or from an increased rate of glutamine utilization. The failure of de novo glutamine synthesis to rise in situations associated with stress (16, 26) , contributes to glutamine depletion. Yet since glutamine production rate (Ra) was found to be increased in stress, increased rate of glutamine utilization must play a role as well. The primary event leading to glutamine depletion under stress conditions or corticosteroid treatment remains unclear.
The splanchnic bed is a "prime suspect" as a site of increased glutamine utilization during stress. In several animal models of sepsis, increased rates of glutamine splanchnic extraction have been reported (27, 40, 41) , but little is known in humans. In the present paper, the fate of splanchnic glutamine was examined by using the concomitant infusion of (18) , the choice of tracer is unlikely to account for the observed changes in glutamine kinetics associated with prednisone. Accordingly, the 42% fractional extraction in the first pass in healthy controls under baseline conditions in the present report is consistent with the 50 -74% extraction of enterally administered glutamine documented in earlier studies (4, 17, 18, 33) . Consistent with previous reports, oxidation was the main fate of glutamine, as oxidation accounted for 75% of glutamine flux, compared with 69 and 83% in earlier studies (17, 18) . In addition, Haisch et al. (17) showed that 53% of the glutamine was oxidized specifically upon its first pass in the splanchnic bed.
The primary observation of the present study is that prednisone increased the splanchnic extraction of glutamine by ϳ50%, without altering the fraction of glutamine undergoing oxidation. This result is consistent with those of SuojarantaYlinen et al. (41) , who showed that 2 h after a coronary bypass the splanchnic extraction of glutamine rose by 56%, along with that of alanine, serine, and threonine. In sepsis, glutamine uptake by the gut is decreased (27) . In contrast, endotoxemia was found to be associated with a dramatic rise in glutamine uptake by the liver (2) . We demonstrated that prednisone increased significantly the splanchnic uptake of glutamine. This is consistent with the view that the increase of glutamine splanchnic uptake may be an early event in catabolic states and a major contributor to glutamine depletion under these conditions.
From a therapeutic standpoint, the fact that splanchnic glutamine extraction rate increased under stress conditions suggests that the enteral route may not be optimal to increase glutamine availability in peripheral tissues in acutely ill patients. Moreover the effect of intestinal inflammation on glutamine utilization is unknown. In patients with quiescent Crohn's disease, glutamine splanchnic extraction and oxidation were found unchanged compared with healthy controls (4), but the effects of acute intestinal inflammation, and, with glucocorticosteroids, on glutamine uptake have yet to be determined.
Despite increased extraction in the splanchnic bed, the rate of glutamine oxidation failed to increase in our prednisonetreated healthy subjects. The ultimate fate of the glutamine extracted in the splanchnic bed remains to be elucidated. Glutamine is known to play a pivotal role in the gut, because glutamine not only serves as a preferred fuel for the enterocytes but also helps maintain rates of intestinal protein synthesis (8, 30, 31) and cell integrity and stimulates immune function as well (9) . During inflammation, increased glutamine consumption by lymphocytes and macrophages in gut-associated lymphoid tissue (GALT) could occur, as these cells are avidly utilizing glutamine (27) . Yet increased use of glutamine by GALT should increase its oxidation. Alternatively, increased splanchnic glutamine extraction may serve to enhance arginine availability, via citrulline synthesis (7, 13, 15, 44, 45, 48, 49) , or the synthesis of glutathione, an antioxidant tripeptide involved in the maintaining of redox status in the intestinal mucosa, particularly under septic conditions (3, 20, 25, 42) .
In summary, we confirm that oral prednisone administration, even to healthy volunteers, increases glutamine Ra because of an increased glutamine de novo synthesis. In addition, we show that a 6-day prednisone treatment induces an increased rate of glutamine extraction in the splanchnic bed, without any change in glutamine oxidation. Although the fate of nonoxidized glutamine in splanchnic bed remains to be ascertained, the increased rate of glutamine splanchnic extraction may serve to maintain intestinal mucosal protein synthesis or immune function or help maintain the enhanced supply of glutathione or arginine that are in increased demand during critical illness. These data further suggest that glutamine supplementation may be important to maintain the metabolic needs of the gut and splanchnic tissues during catabolic stress. The latter deserves further study.
